PL1781657T3 - Leki o aktywności wobec receptora HM74A - Google Patents

Leki o aktywności wobec receptora HM74A

Info

Publication number
PL1781657T3
PL1781657T3 PL05707363T PL05707363T PL1781657T3 PL 1781657 T3 PL1781657 T3 PL 1781657T3 PL 05707363 T PL05707363 T PL 05707363T PL 05707363 T PL05707363 T PL 05707363T PL 1781657 T3 PL1781657 T3 PL 1781657T3
Authority
PL
Poland
Prior art keywords
medicaments
receptor activity
hm74a receptor
hm74a
activity
Prior art date
Application number
PL05707363T
Other languages
English (en)
Inventor
Shahzad Sharooq Rahman
Ivan Leo Pinto
Neville Hubert Nicholson
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PL1781657T3 publication Critical patent/PL1781657T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
PL05707363T 2004-02-14 2005-02-10 Leki o aktywności wobec receptora HM74A PL1781657T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds
EP05707363A EP1781657B1 (en) 2004-02-14 2005-02-10 Medicaments with hm74a receptor activity
PCT/EP2005/001449 WO2005077950A2 (en) 2004-02-14 2005-02-10 Medicaments with hm74a receptor activity

Publications (1)

Publication Number Publication Date
PL1781657T3 true PL1781657T3 (pl) 2013-08-30

Family

ID=34864831

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05707363T PL1781657T3 (pl) 2004-02-14 2005-02-10 Leki o aktywności wobec receptora HM74A

Country Status (26)

Country Link
US (5) US7713982B2 (pl)
EP (1) EP1781657B1 (pl)
JP (2) JP5001012B2 (pl)
KR (1) KR101100601B1 (pl)
CN (2) CN101103030B (pl)
AR (1) AR047669A1 (pl)
AU (1) AU2005212816C1 (pl)
BR (1) BRPI0507604A (pl)
CA (1) CA2556073C (pl)
CY (1) CY1114022T1 (pl)
DK (1) DK1781657T3 (pl)
ES (1) ES2406732T3 (pl)
HK (1) HK1104530A1 (pl)
HR (1) HRP20130406T1 (pl)
IL (1) IL177051A (pl)
MA (1) MA28357A1 (pl)
MY (1) MY148937A (pl)
NO (1) NO337281B1 (pl)
NZ (1) NZ548496A (pl)
PE (1) PE20060317A1 (pl)
PL (1) PL1781657T3 (pl)
PT (1) PT1781657E (pl)
SG (1) SG157242A1 (pl)
SI (1) SI1781657T1 (pl)
TW (1) TWI350289B (pl)
WO (1) WO2005077950A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070930A1 (en) * 1999-11-12 2009-06-17 Biogen Idec MA, Inc. Polycycloalkylpurines as adenosine receptor antagonists
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
BRPI0507604A (pt) * 2004-02-14 2007-07-03 Smithkline Beecham Corp medicamentos com atividade de receptor hm74a
JP5254620B2 (ja) 2004-12-03 2013-08-07 メルク・シャープ・アンド・ドーム・コーポレーション Ｃｂ１アンタゴニストとしての置換ピペラジン
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
JP4975739B2 (ja) 2005-05-17 2012-07-11 シェーリング コーポレイション 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CA2611910A1 (en) 2005-06-14 2006-12-21 F. Hoffmann-La Roche Ag Anthranilic acid derivatives
SI1901731T1 (sl) 2005-06-28 2011-07-29 Merck Sharp & Dohme Niacin receptorski antagonisti, sestavki vsebujoäśi take spojine in postopki zdravljenja
DE602006018151D1 (de) * 2005-08-10 2010-12-23 Glaxosmithkline Llc Xanthinderivate als selektive hm74a-agonisten
CA2637717A1 (en) * 2006-01-20 2007-08-02 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
AU2007253513B2 (en) * 2006-05-23 2010-07-08 F. Hoffmann-La Roche Ag Pyridopyrimidinone derivatives
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
CN101466714B (zh) 2006-06-23 2013-02-06 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
AR061626A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
EP2139895A1 (en) 2007-03-23 2010-01-06 F. Hoffmann-Roche AG Aza-pyridopyrimidinone derivatives
CN102245606B (zh) * 2008-12-08 2014-08-20 葛兰素史密斯克莱有限责任公司 新化合物
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
CN102276610B (zh) * 2011-05-04 2013-01-09 北京工业大学 N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-氯茶碱的制备方法
CN107206002B (zh) * 2015-01-30 2019-07-16 上海珊顿医药科技有限公司 尿酸性或痛风性疾病的预防或治疗
CN104892610B (zh) * 2015-05-27 2016-08-24 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 一种黄嘌呤化合物的制备方法
CA3032229A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
US11083199B2 (en) 2017-01-10 2021-08-10 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
CA3155338A1 (en) * 2019-09-25 2021-04-01 Goldfinch Bio, Inc. Xanthine cb1 inhibitors
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) * 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
AU3725893A (en) * 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
ATE230990T1 (de) 1992-03-04 2003-02-15 Cell Therapeutics Inc Enantiomere hydroxylierte xanthinverbindungen
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US5780476A (en) 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en) 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6103730A (en) 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
WO1995022546A1 (en) 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
MXPA01010143A (es) 1999-04-09 2003-07-14 Cell Therapeutics Inc Derivados de xantina y analogos como inhibidores de transmision de senales celulares.
US20030207901A1 (en) 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
WO2001016134A1 (en) * 1999-08-31 2001-03-08 Vanderbilt University Selective antagonists of a2b adenosine receptors
US6855817B2 (en) * 2000-07-21 2005-02-15 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) * 2000-07-28 2003-01-24 Inside Technologies Dispositif electronique portable comprenant plusieurs circuits integres sans contact
WO2002024194A2 (en) * 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
KR100883277B1 (ko) 2001-02-24 2009-02-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 크산틴 유도체 및 이의 제조방법
US20040254224A1 (en) * 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
BRPI0507604A (pt) * 2004-02-14 2007-07-03 Smithkline Beecham Corp medicamentos com atividade de receptor hm74a
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
DE602006018151D1 (de) 2005-08-10 2010-12-23 Glaxosmithkline Llc Xanthinderivate als selektive hm74a-agonisten
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
CN102245606B (zh) * 2008-12-08 2014-08-20 葛兰素史密斯克莱有限责任公司 新化合物
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Also Published As

Publication number Publication date
PT1781657E (pt) 2013-05-23
IL177051A0 (en) 2006-12-10
MA28357A1 (fr) 2006-12-01
AU2005212816B2 (en) 2009-07-23
JP2008120831A (ja) 2008-05-29
TW200536537A (en) 2005-11-16
TWI350289B (en) 2011-10-11
HK1104530A1 (en) 2008-01-18
US20150080418A1 (en) 2015-03-19
AR047669A1 (es) 2006-02-01
US8268839B2 (en) 2012-09-18
EP1781657B1 (en) 2013-03-27
SI1781657T1 (sl) 2013-07-31
DK1781657T3 (da) 2013-06-10
WO2005077950A2 (en) 2005-08-25
US20100010021A1 (en) 2010-01-14
BRPI0507604A (pt) 2007-07-03
AU2005212816C1 (en) 2010-03-04
WO2005077950A3 (en) 2007-04-19
US20100160354A1 (en) 2010-06-24
CN101863888A (zh) 2010-10-20
US20070135456A1 (en) 2007-06-14
JP2007522176A (ja) 2007-08-09
NO20064151L (no) 2006-11-06
AU2005212816A1 (en) 2005-08-25
CY1114022T1 (el) 2016-07-27
US8394808B2 (en) 2013-03-12
MY148937A (en) 2013-06-14
HRP20130406T1 (hr) 2013-06-30
IL177051A (en) 2013-01-31
CN101103030A (zh) 2008-01-09
ES2406732T3 (es) 2013-06-07
NO337281B1 (no) 2016-02-29
CN101863888B (zh) 2012-07-18
JP5001012B2 (ja) 2012-08-15
KR101100601B1 (ko) 2011-12-29
CA2556073C (en) 2012-01-10
US20130150383A1 (en) 2013-06-13
CN101103030B (zh) 2010-10-13
CA2556073A1 (en) 2005-08-25
NZ548496A (en) 2010-02-26
JP5020848B2 (ja) 2012-09-05
US7713982B2 (en) 2010-05-11
PE20060317A1 (es) 2006-06-22
SG157242A1 (en) 2009-12-29
EP1781657A2 (en) 2007-05-09
KR20060126772A (ko) 2006-12-08

Similar Documents

Publication Publication Date Title
SI1781657T1 (sl) Zdravila z aktivnostjo na receptor hm74a
IL182586A0 (en) Xanthine derivatives with hm74a receptor activity
GB2415396B (en) Catalysts
ZA200608781B (en) Catalysts
GB0400166D0 (en) Catalyst
GB0420156D0 (en) Catalysis
EP1818098A4 (en) hONEYCOMB STRUCTURE
EP1795261A4 (en) ALVEOLAR STRUCTURE
EP1790612A4 (en) NANOCAPSULE TYPE STRUCTURE
GB0500643D0 (en) Medicaments
GB0426473D0 (en) Catalysts
HK1079199A1 (en) Indazolamides with analgesic activity
GB0411850D0 (en) Spacing arrangement
EP1714648A4 (en) COMBINATION DRUGS
GB0412874D0 (en) Novel pharmaceuticals
IL180487A0 (en) Medicament
GB0409901D0 (en) Catalysts
EP1853258A4 (en) DRUGS
GB0402491D0 (en) Medicaments
ZA200703231B (en) Xanthine derivatives with HM74A receptor activity
GB0403733D0 (en) Medicaments
GB0419851D0 (en) Catalysts
GB0424565D0 (en) Activity aid
HRP20040318A2 (en) Furochromen derivative with anti-inflammaroty activity
EP1814422A4 (en) BED CONSTRUCTION